Abstract: The present invention relates to the biological production of methane (Biogas) by co-culture in an aerobic atmosphere of a methanogenic bacterium and of an anaerobic bacterium capable of producing hydrogen, in a culture medium comprising or being supplemented with carbohydrate compound(s), notably starch and/or sugars, and supplemented with antioxidant compound(s).

Abstract: The invention relates to a specific antibody directed against, for use for treating graft versus host disease.

Abstract: The present invention relates to a method for cultivating in vitro in an acellular culture medium, bacteria for which the growth is sensitive to oxygen content, said bacterium being selected from anaerobic bacteria and intracellular micro-aerophilic bacteria, characterized in that uric acid is added into said acellular culture medium, and said bacterium is cultivated in said culture medium in the presence of oxygen.

Abstract: The invention relates to novel polymers containing grafted sodium or lithium bis(sulfonyl)imides, to the methods for the production thereof, and to the uses of same as electrolytes in batteries.

Abstract: The invention relates to novel polymers containing grafted sodium or lithium sulphonamides, production methods thereof and uses of same as electrolytes in batteries.

Abstract: The present invention provides antibodies directed against ICOS or a derivative thereof which neutralize ICOS engagement on Treg by inhibiting the fixation between ICOS and ICOS-L and abrogate proliferation of Treg induced by plasmacytoid dendritic cells. The present invention further provides antibodies directed against ICOS or a derivative thereof which induce IL-10 and IFN? production, induce CD4+ T cells proliferation, reduce Tconv proliferation, and increase the immunosuppressive function of Treg.

Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of:—a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and,—a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.

Abstract: A rotor including blades rotating around a rotation axis (X), each blade being configured to transmit to the rotation axis, during a revolution of the rotor around the rotation axis, under the effect of the flow of a fluid, alternately a driving torque that rotates the rotor, and a resistant torque tending to go against the rotation of the rotor, each blade including in a region of an outer longitudinal edge of the blade, a flexible part configured to retract towards the inside of the rotor, when the blade transmits the resistant torque to the rotation axis of the rotor, and to switch to a position extended towards the outside of the rotor, during the rotor half-revolution following a maximum retraction position, when the blade transmits the driving torque to the rotation axis of the rotor, the flexible part being driven only under the effect of the flow of the fluid.

Abstract: The invention relates to a method for texturing a semiconductor substrate (1), comprising steps consisting in forming a plurality of cavities of random shapes, depths and distribution, in an etch mask (2), by means of non-homogeneous reactive-ion etching, forming a first rough random design, and etching the substrate using the etch mask, by means of reactive-ion etching, in such a way as to transfer the first rough random design into the substrate and to produce a second rough random design (200), comprising cavities (20) of random shapes, depths (d2r) and distribution, on the surface of the substrate.

Abstract: The present invention relates to the general field of treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the treatment of immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.

Abstract: The present invention relates to a method for displaying a graphical interface having display areas including a reference area, wherein each file of a file set is displayed in the form of an icon in one of the display areas, and each file of the file set contains a unique identifier identifying the file, and processing a command for inserting into the file set a selected pre-existing file which does not belong to the file set, the processing of the insertion command including the steps of: generating a new file in the file set, from the content of the selected pre-existing file, generating a unique identifier identifying the new file, and inserting into the new file the generated unique identifier and a reference link generated from a file identifier corresponding to each icon located in the reference area.

Abstract: The present invention relates to methods for selecting binders by phage display and masked selection. More particularly, the present invention relates to a method for selecting a plurality of binders specific for at least one relevant target comprising screening a phage binder library of binders against the relevant target in presence of a plurality of binders obtained from a library of binders directed against at least one irrelevant target and positively selecting the binders that are specific for the at least one relevant target.

Abstract: The present invention relates to compositions and methods for modulating angiogenesis in vivo, ex vivo or in vitro. More particularly, the invention relates to a soluble CD 146 protein usable in the context of human therapy, as well as to corresponding antibodies. Particular forms of CD 146, herein described, may be used to mobilize, in vivo or ex vivo, both mature and immature endothelial cells, as well as to increase their influence on angiogenesis. The invention also relates to compositions comprising such compounds, particularly pharmaceutical or diagnostic compositions, including kits and the like, as well as methods of therapy or diagnosis using said compounds, compositions and cells.

Abstract: The present invention relates to antigen binding formats for use in therapeutic treatments or diagnostic assays. The present invention relates to an antigen-binding format consisting of: —a first fusion protein wherein the CH1 constant domain of an antibody is fused i) by its N-terminal end to the C-terminal end of a variable domain of an antibody and ii) by its C-terminal end to the N-terminal end of a variable domain of an antibody and, —a second fusion protein wherein the CL constant domain of an antibody is fused by its N-terminal end to the C-terminal end of a variable domain of an antibody.

Abstract: The invention relates to a compound which inhibits the importation of chloride into neurons or a compound which improve the outflow of chloride from neurons for use in the treatment of autism in a baby or a fetus in need thereof.

Abstract: A device for quantifying a useful thermal energy available in a tank for storing a heated or cooled fluid or solid includes: a plurality of thermoelectric converters configured to be distributed in plural locations of the storage tank; an electric circuit interconnecting the thermoelectric converters; a device measuring a single electrical variable of the electric circuit; and a converter converting a single measurement of the single electrical variable into a value for quantification of the useful thermal energy available in the storage tank.

Abstract: The present invention relates to the use of polyaminoisoprenyl derivatives in antibiotic or antiseptic treatment of bacteria including those presenting multiple drug resistance (MDR), in particular as efflux pump inhibitors. It also relates to novel polyaminoisoprenyl derivatives, compositions comprising the same, process for preparing the same, and use thereof in antibiotic or antiseptic treatment.

Abstract: A device for detecting radiation particles comprising at least one sensor for sensing radiation particles, capable of supplying an electrical pulse when it is traversed by at least one radiation particle, and at least one detection circuit comprising a voltage-controlled oscillator to which said electrical pulse originating from the sensor is supplied as the control voltage. The voltage-controlled oscillator is a ring oscillator.

Abstract: This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.

Abstract: The invention relates to a method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, optionally in the presence of at least one colipide, enabling the encapsulation of therapeutic agents, especially anti-tumoral agents, and the use thereof for the transport and vectorization of therapeutic agents, especially anti-tumoral agents.